fig5

2017-2023: state of the art of gene therapies in rare diseases in Europe: the dynamics of clinical R&D, new approved treatments and expected therapies in the pipelines

Figure 5. Gene therapies in rare disease - information about stage of development. (A) pie chart representation of development stages of the 73 identified gene therapies ranging from phase I, II, and III to market authorization; (B) Diagram representation of the absolute number of gene therapies in development associated with both their therapeutic areas and their respective stages of development (from phase I to market authorization (in Europe and/or in US). The absolute number of individual therapies under development is presented to the right of each graph; (C) Table indicating information about new gene therapies for rare diseases authorized between 2017 and 2023; the information will cover associated therapeutic area, related condition, name of the product, sponsor name and year of approval (for authorized products), as well as the year of start or year of completion for gene therapies in stage III of development.

Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/